Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. The short person has left for the local schoolhouse — the last full day before rigorous testing begins — and the official mascots are happily snoozing below windows where a warm sun and cool breeze can be felt. As for us, yes, we are quaffing cups of stimulation, since there is much to be done and we need all the help we can get. Perhaps you can relate. Meanwhile, here are some tidbits. Have a wonderful day and please do keep in touch …

For Sen. Robert Menendez (D-N.J.), Republican challenger Bob Hugin’s record as the top Celgene (CELG) executive is fertile ground for attacks on the campaign trail. Now he just tweaked his opponent again, adding his name to legislation that Hugin fought against while at Celgene, tells us. Menendez became one of the latest co-sponsors of the CREATES Act, which is designed to make it easier for generic manufacturers to get supplies of brand-name drugs so they can produce lower-cost alternatives.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy